{"id":"13016731c83d","type":"article","url":"https://hartvaat.nl/2017/08/08/prasugrel-of-ticagrelor-bij-stemi-met-diabetes/","title":"Prasugrel of ticagrelor bij STEMI met diabetes","title_en":"Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog"],"tags":["diabetes-en-hart","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.117.028745","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.117.028745","authors":["Gennaro Sardella","Massimo Mancone","Rocco Edoardo Stio","Erika Cavallo","Angelo Di Roma","Riccardo Colantonio","Simone Calcagno"],"significance":6,"published":"2017-08-08","source_date":"2017-08-08","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This analysis compared prasugrel with ticagrelor specifically in STEMI patients with diabetes, investigating whether the optimal P2Y12 inhibitor choice differs in this high-risk subpopulation.","created":"2026-07-03T10:26:50Z","updated":"2026-07-03T13:26:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse die prasugrel vergeleek met ticagrelor specifiek bij STEMI-patiënten met diabetes. Onderzoekt de optimale P2Y12-remmerkeuze bij deze hoogrisico-subgroep.","abstract_original":""}